Journal Mobile Options
Table of Contents
Vol. 73, Suppl. 1, 2006
Issue release date: February 2006
Digestion 2006;73:5–12

Enteric Flora in Health and Disease

Guarner F.
Digestive System Research Unit, University Hospital Vall d’Hebron, Barcelona, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The human gut is the natural habitat for a large and dynamic bacterial community. Recently developed molecular biology tools suggest that a substantial part of these bacterial populations are still to be described. However, the relevance and impact of resident bacteria on host’s physiology and pathology is well documented. Major functions of the gut microflora include metabolic activities that result in salvage of energy and absorbable nutrients, protection of the colonized host against invasion by alien microbes, and important trophic effects on intestinal epithelia and on immune structure and function. Gut bacteria play an essential role in the development and homeostasis of the immune system. It is important to underscore that the specialised lymphoid follicles of the gut mucosa are the major sites for induction and regulation of the immune system. On the other hand, there is evidence implicating the gut flora in certain pathological conditions, including multisystem organ failure, colon cancer and inflammatory bowel diseases.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Falk PG, Hooper LV, Midtvedt T, Gordon JI: Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev 1998;62:1157–1170.
  2. Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003;361:512–519.
  3. Suau A, Bonnet R, Sutren M, Godon JJ, Gibson G, Collins MD, Dore J: Direct rDNA community analysis reveals a myriad of novel bacterial lineages within the human gut. Appl Environ Microbiol 1999;65:4799–4807.
  4. Tannock GW: Molecular assessment of intestinal microflora. Am J Clin Nutr 2001;73(suppl):410S–414S.
  5. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans ADL, de Vos WM: Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002;68:3401–3407.
  6. Kimura K, McCartney AI, McConnell MA, Tannock GW: Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains. Appl Environ Microbiol 1997;63:3394–3398.
  7. Hooper LV, Midtvedt T, Gordon JI: How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002;22:283–307.
  8. Macfarlane GT, Cummings JH, Allison C: Protein degradation by human intestinal bacteria. J Gen Microbiol 1986;132:1647–1656.
  9. Smith EA, Macfarlane GT: Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol 1996;81:288–302.
  10. Hooper LV, Xu J, Falk PG, Midtvedt T, Gordon JI: A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci USA 1999;96:9833–9838.
  11. Brook I: Bacterial interference. Crit Rev Microbiol 1999;25:155–172.
  12. Lievin V, Peiffer I, Hudault S, Rochat F, Brassart D, Neeser JR, Servin AL: Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000;47:646–652.
  13. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI: Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291:881–884.
  14. Butler JE, Sun J, Weber P, Navarro P, Francis D: Antibody repertoire development in fetal and newborn piglets. III. Colonization of the gastrointestinal tract selectively diversifies the preimmune repertoire in mucosal lymphoid tissues. Immunology 2000;100:119–130.
  15. Fagarasan S, Muramatsu M, Suzuki K, Nagaoka H, Hiai H, Honjo T: Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 2002;298:1414–1427.

    External Resources

  16. Bourlioux P, Braesco V, Koletzko B, Guarner F: The intestine and its microflora are partners for the protection of the host. Am J Clin Nutr 2003;2003;78:675–683.

    External Resources

  17. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782–787.
  18. Elewaut D, DiDonato JA, Kim JM, et al: NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol 1999;163:1457–1466.
  19. Maaser C, Kagnoff MF: Role of the intestinal epithelium in orchestrating innate and adaptive mucosal immunity. Z Gastroenterol 2002;40:525–529.
  20. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000;47:79–87.
  21. Borruel N, Casellas F, Antolín M, Carol M, Llopis M, Espín E, Naval J, Guarner F, Malagelada JR: Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 2003;98:865–870.
  22. Borruel N, Carol M, Casellas F, Antolín M, de Lara F, Espín E, Naval J, Guarner F, Malagelada JR: Increased mucosal TNF-α production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659–664.
  23. Carol M, Borruel N, Antolín M, Casellas F, Guarner F, Malagelada JR: Lactobacillus casei can overcome resistance to apoptosis in lymphocytes from patients with Crohn’s disease. Gastroenterology 2003;124:A321.

    External Resources

  24. Brandtzaeg PE: Current understanding of gastrointestinal immunoregulation and its relation to food allergy. Ann NY Acad Sci 2002;964:13–45.
  25. Cummings JH, Antoine JM, Azpiroz F, Bourdet-Sicard R, Brandtzaeg P, Calder PC, Gibson GR, Guarner F, Isolauri E, Pannemans D, Shortt C, Tuijtelaars S, Watzl B: PASSCLAIM – gut health and immunity. Eur J Nutr 2004;43(suppl 2):118–173.
  26. Rook GA, Brunet LR: Give us this day our daily germs. Biologist (London) 2002;49:145–149.
  27. Lin HC: Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852–858.
  28. Lichtman SM: Baterial translocation in humans. J Pediatr Gastroenterol Nutr 2001;33:1–10.
  29. Rafter J, Glinghammar B: Interactions between the environment and genes in the colon. Eur J Cancer Prev 1998;7(suppl 2):S69–S74.

    External Resources

  30. Shanahan F: Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622–635.
  31. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I: Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365–375.
  32. Pirzer U, Schönhaar A, Fleischer B, Hermann E, Meyer zum Büschenfelde KH: Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn’s disease. Lancet 1991;338:1238–1239.
  33. D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262–267.
  34. Casellas F, Borruel N, Papo M, Guarner F, Antolín M, Videla S, Malagelada JR: Anti-inflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflammatory Bowel Dis 1998;4:1–5.
  35. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG: Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001;357:1902–1904.
  36. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, Doré J: Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut 2003;52:237–242.
  37. Guarner F, Schaafsma G. Probiotics. Int J Food Microbiol 1998;39:237–238.
  38. Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401–1412.
  39. D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ: Probiotics in prevention of antibiotic associated diarrhoea: metaanalysis. Br Med J 2002;324:1361–1366.

    External Resources

  40. Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, Gasbarrini A: Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002;16:1461–1467.
  41. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH: Feeding of Bifidibacterium bifidum and Streptococcus termophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;334:1046–1049.
  42. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W: Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001;138:361–365.
  43. Mastretta E, Longo P, Laccisaglia A, Balbo L, Russo R, Mazzaccara A, Gianino P: Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr 2002;35:527–531.
  44. Oberhelman RA, Gilman RH, Sheen P, Taylor DN, Black RE, Cabrera L, Lescano AG, Meza R, Madico G: A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr 1999;134:15–20.
  45. Pedone CA, Arnaud CC, Postaire ER, Bouley CF, Reinert P: Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 2000;54:568–571.
  46. Marteau P, Seksik P, Jian R: Probiotics and intestinal health effects: a clinical perspective. Br J Nutr 2002;88(suppl 1):S51–S57.

    External Resources

  47. Szajewska H, Mrukowicz JZ: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001;33:S17–S25.

    External Resources

  48. Van Niel CW, Feudtner C, Garrison MM, Christakis DA: Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002;109:678–684.
  49. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ: Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002;47:2625–2634.
  50. Gibson GR, Beatty ER, Wang X, Cummings JH: Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995;108:975–982.
  51. Saavedra JM, Tschernia A: Human studies with probiotics and prebiotics: clinical implications. Br J Nutr 2002;87(suppl 2):S241–S246.

    External Resources

  52. Cummings JH, Christie S, Cole TJ: A study of fructo-oligosaccharides in the prevention of travellers’ diarrhoea. Aliment Pharmacol Ther 2001;15:1139–1145.
  53. Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S: Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002;89:1103–1107.
  54. Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, Bengmark S, Neuhaus P: Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation – a randomized, double-blind trial. Am J Transplant 2005;5:125–130.
  55. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620–1633.
  56. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, Isolauri E, Moreau MC, Roberfroid M, Rowland I: Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80(suppl 1):S147–S171.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50